GlassScriptPhysician profile
Michael S Mchale
NPI 1124017256
$811.07
in general payments reported to CMS, 2019-2025
21 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.98 · 2020: $210 · 2021: $178 · 2023: $106 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $279.58 | 2025 | Stratafix, Vistaseal |
| E.R. Squibb & Sons, L.L.C. | $99.41 | 2020-2023 | Reblozyl |
| Seagen INC. | $77.57 | 2020-2021 | |
| Amgen INC. | $42.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.13 | 2020-2021 | |
| Pharmaessentia USA Corporation | $32.85 | 2023 | Besremi |
| Lilly USA, LLC | $32.04 | 2020 | |
| Incyte Corporation | $28.91 | 2020 | |
| Sirtex Medical INC | $20.74 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $16.75 | 2021 | |
| Array Biopharma INC | $15.35 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.26 | 2020 | |
| Myovant Sciences INC. | $13.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.55 | 2020 | |
| Janssen Biotech, INC. | $12.94 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.65 | 2021 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Pfizer INC. | $11.46 | 2021 | |
| Astellas Pharma US INC | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mchale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.